Haleon is beefing up its stake in Chinese OTC joint venture TSKF and has secured an option to take full control of the business in the future.
The UK-based consumer health giant has agreed a deal to acquire an additional 33% of equity interest in TSKF for RMB4.47bn ($637m), taking its share of the business from 55% to 88%
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?